EARLY APPROACHES IN MANAGEMENT OF SARS-CoV-2 INFECTION

Abstract

          SARS-CoV-2 infection is an infectious pathology that currently poses an exceptional threat to global public health and safety. Of great necessity was the rapid discovery of the effective vaccine, thus leading to the acceleration of ethical approaches to research, including by conducting controlled clinical trials. The therapeutic protocol has always been updated, since the beginning of the pandemic, March 2020, for the correct therapeutic control.

          We conducted a study on cases of SARS-CoV-2 infection hospitalized between 15 March and 30 November 2020 in the Clinical Hospital of Infectious Diseases “St. Parascheva” Iasi, with various forms of the disease.

          More than 30% of cases consisted of severe and critical forms in people with multiple comorbidities, requiring evaluation, monitoring and treatment in the Intensive Care Unit. The treatment regimens used, according to the national protocol periodically revised, included association of antivirals, anti-inflammatory medication and immunomodulatory monoclonal antibodies. The risk of various therapeutic associations has always been assessed in order to maximize the effectiveness of treatment and to promote favorable evolutions.

          Management of patients with SARS-CoV-2 infection, which also associates other pathologies, requires interdisciplinary collaboration, while still maintaining ethical standards. Nevertheless, the overall effectiveness of immunisation with available SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality in general population.